drugset
drugset / Trial / NCT01767896

Phase-3 Study of ASP7374, Cell-culture-derived Influenza Vaccine

NCT01767896 ↗

Phase 3 Completed 1020 enrolled UMN Pharma Inc.
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to compare immunogenicity and safety of ASP7374 (cell-culture derived influenza vaccine) with those of approved egg-derived trivalent inactivated vaccine (TIV) in elderly subjects.

Timeline

Start
2012-10
Primary completion
2013-03
Completion
2013-03

Drugs

EvaluationDrugModalityDoseRoute
Subject ASP7374 Vaccine — Subcutaneous
Comparator approved egg-derived TIV Vaccine — Subcutaneous

Indications

influenza